Attillaps’ platform of small molecules is focused on treating cutaneous inflammatory conditions. Our lead indications are rosacea and blepharitis. Other indications of interest include meibomian gland dysfunction, atopic dermatitis, acne vulgaris, ocular rosacea, and hidradenitis suppurativa.
We have repurposed AChE inhibitors. Our molecules can effectively target inflammation in the skin and eyelid margin. The topical and ophthalmic application of these AChE inhibitors limits systemic exposure, further increasing the known safety of these molecules while effectively targeting the cutaneous inflammation.